Switch theme
Sign up to access all valuation multiples
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
1998
254
LTM Revenue $85.4M
LTM EBITDA $8.5M
$519M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Polynovo has a last 12-month revenue (LTM) of $85.4M and a last 12-month EBITDA of $8.5M.
In the most recent fiscal year, Polynovo achieved revenue of $67.6M and an EBITDA of $2.7M.
Polynovo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Polynovo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $85.4M | XXX | $67.6M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $64.0M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $8.5M | XXX | $2.7M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $6.4M | XXX | $0.8M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 1% | XXX | XXX | XXX |
| Net Profit | $4.4M | XXX | $3.4M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Polynovo's stock price is AUD 1 (or $1).
Polynovo has current market cap of AUD 805M (or $527M), and EV of AUD 792M (or $519M).
See Polynovo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $519M | $527M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Polynovo has market cap of $527M and EV of $519M.
Polynovo's trades at 6.8x EV/Revenue multiple, and 96.5x EV/EBITDA.
Equity research analysts estimate Polynovo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Polynovo has a P/E ratio of 118.8x.
See valuation multiples for Polynovo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $527M | XXX | $527M | XXX | XXX | XXX |
| EV (current) | $519M | XXX | $519M | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 61.3x | XXX | 96.5x | XXX | XXX | XXX |
| EV/EBIT | 81.2x | XXX | 152.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 118.8x | XXX | 138.8x | XXX | XXX | XXX |
| EV/FCF | -55.2x | XXX | -111.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPolynovo's last 12 month revenue growth is 24%
Polynovo's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Polynovo's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Polynovo's rule of X is 69% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Polynovo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 100% | XXX | 429% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 94% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Polynovo acquired XXX companies to date.
Last acquisition by Polynovo was XXXXXXXX, XXXXX XXXXX XXXXXX . Polynovo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Polynovo founded? | Polynovo was founded in 1998. |
| Where is Polynovo headquartered? | Polynovo is headquartered in Australia. |
| How many employees does Polynovo have? | As of today, Polynovo has 254 employees. |
| Is Polynovo publicy listed? | Yes, Polynovo is a public company listed on ASX. |
| What is the stock symbol of Polynovo? | Polynovo trades under PNV ticker. |
| When did Polynovo go public? | Polynovo went public in 1998. |
| Who are competitors of Polynovo? | Similar companies to Polynovo include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Polynovo? | Polynovo's current market cap is $527M |
| What is the current revenue of Polynovo? | Polynovo's last 12 months revenue is $85.4M. |
| What is the current revenue growth of Polynovo? | Polynovo revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Polynovo? | Current revenue multiple of Polynovo is 6.1x. |
| Is Polynovo profitable? | Yes, Polynovo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Polynovo? | Polynovo's last 12 months EBITDA is $8.5M. |
| What is Polynovo's EBITDA margin? | Polynovo's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Polynovo? | Current EBITDA multiple of Polynovo is 61.3x. |
| What is the current FCF of Polynovo? | Polynovo's last 12 months FCF is -$9.4M. |
| What is Polynovo's FCF margin? | Polynovo's last 12 months FCF margin is -11%. |
| What is the current EV/FCF multiple of Polynovo? | Current FCF multiple of Polynovo is -55.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
